Therefore, this study examined the potential for expansion and adaptation of simultaneous CBP/p300 inhibitors for use against cancers with SS18–SSX fusion and the majority of SMARCA4/SMARCA2-deficient in addition to SMARCB1 deficient, which was reported previously (19). Here, SMARCA2 is linked to cancer.